291 related articles for article (PubMed ID: 35586474)
1. New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy.
Kumar K; Rani V; Mishra M; Chawla R
Curr Res Pharmacol Drug Discov; 2022; 3():100103. PubMed ID: 35586474
[TBL] [Abstract][Full Text] [Related]
2. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in mechanism-based chemotherapy drug-siRNA pairs in co-delivery systems for cancer: A review.
Wang M; Wang J; Li B; Meng L; Tian Z
Colloids Surf B Biointerfaces; 2017 Sep; 157():297-308. PubMed ID: 28601758
[TBL] [Abstract][Full Text] [Related]
4. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.
Gandhi NS; Tekade RK; Chougule MB
J Control Release; 2014 Nov; 194():238-56. PubMed ID: 25204288
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy.
Xiao B; Ma L; Merlin D
Expert Opin Drug Deliv; 2017 Jan; 14(1):65-73. PubMed ID: 27337289
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in delivery of drug-nucleic acid combinations for cancer treatment.
Li J; Wang Y; Zhu Y; Oupický D
J Control Release; 2013 Dec; 172(2):589-600. PubMed ID: 23624358
[TBL] [Abstract][Full Text] [Related]
7. Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.
Pan J; Mendes LP; Yao M; Filipczak N; Garai S; Thakur GA; Sarisozen C; Torchilin VP
Eur J Pharm Biopharm; 2019 Mar; 136():18-28. PubMed ID: 30633973
[TBL] [Abstract][Full Text] [Related]
8. Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect.
Chen M; Wang L; Wang F; Li F; Xia W; Gu H; Chen Y
Int J Nanomedicine; 2019; 14():3557-3569. PubMed ID: 31190812
[No Abstract] [Full Text] [Related]
9. Nanoplatform-based natural products co-delivery system to surmount cancer multidrug-resistant.
Liang Y; Liu ZY; Wang PY; Li YJ; Wang RR; Xie SY
J Control Release; 2021 Aug; 336():396-409. PubMed ID: 34175367
[TBL] [Abstract][Full Text] [Related]
10. Polymers in the Co-delivery of siRNA and Anticancer Drugs for the Treatment of Drug-resistant Cancers.
Sun H; Yarovoy I; Capeling M; Cheng C
Top Curr Chem (Cham); 2017 Apr; 375(2):24. PubMed ID: 28176270
[TBL] [Abstract][Full Text] [Related]
11. The importance of co-delivery of nanoparticle-siRNA and anticancer agents in cancer therapy.
Khelghati N; Soleimanpour Mokhtarvand J; Mir M; Alemi F; Asemi Z; Sadeghpour A; Maleki M; Samadi Kafil H; Jadidi-Niaragh F; Majidinia M; Yousefi B
Chem Biol Drug Des; 2021 Apr; 97(4):997-1015. PubMed ID: 33458952
[TBL] [Abstract][Full Text] [Related]
12. Nano carriers that enable co-delivery of chemotherapy and RNAi agents for treatment of drug-resistant cancers.
Tsouris V; Joo MK; Kim SH; Kwon IC; Won YY
Biotechnol Adv; 2014; 32(5):1037-50. PubMed ID: 24924617
[TBL] [Abstract][Full Text] [Related]
13. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
[TBL] [Abstract][Full Text] [Related]
14. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
[TBL] [Abstract][Full Text] [Related]
15. siRNA-Based Carrier-Free System for Synergistic Chemo/Chemodynamic/RNAi Therapy of Drug-Resistant Tumors.
Jiang Y; Liu Y; Wang M; Li Z; Su L; Xu X; Xing C; Li J; Lin L; Lu C; Yang H
ACS Appl Mater Interfaces; 2022 Jan; 14(1):361-372. PubMed ID: 34931793
[TBL] [Abstract][Full Text] [Related]
16. Codelivery of anticancer drugs and siRNA by mesoporous silica nanoparticles.
Hanafi-Bojd MY; Ansari L; Malaekeh-Nikouei B
Ther Deliv; 2016 Sep; 7(9):649-55. PubMed ID: 27582236
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-induced tumor cell resistance is overcome by synergistic GAPDH-siRNA and chemotherapy co-delivered by long-circulating and cationic-interior liposomes.
Guan J; Sun J; Sun F; Lou B; Zhang D; Mashayekhi V; Sadeghi N; Storm G; Mastrobattista E; He Z
Nanoscale; 2017 Jul; 9(26):9190-9201. PubMed ID: 28650490
[TBL] [Abstract][Full Text] [Related]
18. Acid-degradable core-shell nanoparticles for reversed tamoxifen-resistance in breast cancer by silencing manganese superoxide dismutase (MnSOD).
Cho SK; Pedram A; Levin ER; Kwon YJ
Biomaterials; 2013 Dec; 34(38):10228-37. PubMed ID: 24055523
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of siRNA and etoposide to cancer cells using an MDEA esterquat based drug delivery system.
Popova P; Notabi MK; Code C; Arnspang EC; Andersen MØ
Eur J Pharm Sci; 2019 Jan; 127():142-150. PubMed ID: 30409750
[TBL] [Abstract][Full Text] [Related]
20. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
